CCO Infectious Disease Podcast

DTR-Pseudomonas aeruginosa: Applying Best Practices in Complex Clinical Scenarios

Episode Summary

Hear experts apply the latest data and guidance recommendations on optimizing antimicrobial therapy for complex clinical infections involving Pseudomonas aeruginosa with difficult-to-treat resistance.

Episode Notes

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving Pseudomonas aeruginosa with difficult-to-treat resistance, including: 

• Mechanisms of β-lactam resistance
• Effect of resistance mechanism on susceptibility to antipseudomonal agent
• 2023 IDSA guidance recommendations 
• Activity against newer antipseudomonal β-lactams in the United States
• The latest clinical data by antimicrobial regimen:

              - Ceftolozane/tazobactam
              - Ceftazidime/avibactam
              - Imipenem/cilastatin/relebactam
              - Cefiderocol

• Applying antimicrobial stewardship principles

Program Director:

Trevor Van Schooneveld, MD, FSHEA, FACP  
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska

Faculty:

Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland  
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center|
Baltimore, Maryland

Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine  
Atlanta, Georgia

Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Follow along with a downloadable slideset at: https://clinicaloptions.com/CE-CME/infectious-disease/cmv-prevention-in-sot-recipients/26139

Link to full program: https://bit.ly/40HyvPy